In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Receptor Logic Ltd.

Latest From Receptor Logic Ltd.

Receptor Logic Ltd.

Receptor Logic has a means of making antibodies that mimic the scouting and identifying functions of T-cells by binding to peptides that appear on the surface of cells, within the frame of the major histocompatability complex. The start-up thinks its antibodies will accelerate research on T-cell-stimulating vaccines (versus prophylactic ones) and will ultimately serve as therapeutics in their own right.


Next-Generation Cancer Immunotherapies

New approaches to cancer immunotherapy promise to change the face of cancer care in a way that will reverberate through the field for years to come. In this issue, we profile Borean Pharma, OncoMed Pharmaceuticals and Receptor Logic.


Start-Up Previews (10/05)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Next-Generation Cancer Immunotherapies, features profiles of Borean Pharma, OncoMed Pharmaceuticals, ProNAi Therapeutics and Receptor Logic. Plus these Start-Ups across Health Care: CeraPedics, DiObex and Endothelix.

Selected Start-Ups (6/04)

In Vivo briefly summarizes the technologies of these recently founded companies: AGI Therapeutics Ltd., Angiosyn Inc., etexx Biopharmaceuticals Inc., Nuvios Inc., Orthonics Inc. and Receptor Logic Ltd.

See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools